The Moores Cancer Center is located on the University of California, San Diego campus in the third most populous county in California. The campus is on 1,200 acres of coastal woodland in the research-rich “Golden Triangle” in La Jolla. It is adjacent to a host of biomedical research institutes, including the Burnham Institute, the Salk Institute, the Scripps Research Institute, and the La Jolla Institute for Allergy and Immunology. It is surrounded by over 470 biomedical and biopharmaceutical companies, which makes this one of the most powerful engines of medical progress in the country.
C3: Cancer Center Councils
The San Diego National Cancer Institute Cancer Centers Council (C3) is a collaborative effort between the three NCI-designated Cancer Centers in the San Diego area (UC San Diego Moores Cancer Center, Salk Institute, and Sanford-Burnham) to leverage their collective talents and resources. The initial core facility-based initiative of the C3 focuses on enhancing inter-institutional sharing of a unique core facility at each center. Recharge rates in these cores have been negotiated to be the host institutions’ cancer center member internal rate plus 16% indirect cost. This reduced cost access to unique cores, along with enhanced outreach by the cores, provides valuable new technical resources to the C3 members.
Biorepository Core in the UC San Diego Moores Cancer Center is a developing collection of plasma, serum, RNA stabilized buffy coat, urine, viable tumor samples, and formalin-fixed paraffin-embedded tumor; with associated clinical information. The tumor collection is predominately from breast and gastrointestinal malignancies. The core can provide anonymized samples from the repository, or ongoing sample collection.
Gene Transfer, Targeting and Therapeutics Core (GT3) in the Salk Institute Cancer Center GT3 (formerly called the Viral Vectors core) provides expert consultation for the safe and effective use of viral vector technologies, and offer custom design and production services for multiple viral vector types. The core supports production of custom lentiviral, retroviral, rAAV, G-deleted rabies, and adenoviral vectors.
The Chemical Library Screening core in the Sanford-Burnham Cancer Center is also a part of the C3 collaborative agreement. The core includes: the Assay Development facility that supports the development and optimization of robust and sensitive high throughput-ready assays (384 or 1536 well) with a wide variety of readouts; the Chemical Libraries & High-Throughput Screening facility provides high throughput screening utilizing the core’s focused libraries or broad collections of compounds (>800,000 compounds total) and extensive robotics; and the High Content Screening facility develops assays for screening with high-throughput microscopy, and assists with all aspects of screening and analysis, including algorithm development. These cores are part of the integrated chemical biology and drug discovery efforts in Sanford-Burnham’s Prebys Center.
One of just two U.S. branches of LICR is located on the UC San Diego campus, enabling powerful scientific synergies with the Cancer Center. Ludwig’s top leaders sit on our Senior Leaders Council.
The Cancer Center has very close collaborations with SIO, which is seeking to develop new chemotherapeutic agents from algae and other natural living organisms from the sea.
Cancer Center researchers rely upon the powerful computing power of SDSC, one of just two such centers in the nation and housed on the UC San Diego campus.
LIAI focuses on understanding the immune response to infectious agents and cancers. Located just steps from the Cancer Center, collaborative synergies are a natural byproduct of this proximity.
SDSU, one of four nationally accredited schools of public health in California, is located in one of the most vibrant and culturally diverse areas in the U.S. Our federally funded partnership with SDSU creates research opportunities for diverse populations.
Salk conducts molecular biology and genetics research to provide new understanding and potential new therapies and treatments for a range of diseases, including cancer.
This organization seeks to understand the underlying biological mechanisms that generate good health or, when they go awry, cause disease. With interest in drug discovery, stem cells, nanomedicine and translational medicine, working to discover the next generation of treatments for cancer and other diseases.